Participant of Equinor & Techstar Energy Accelerator 2023 🚀 🌱We believe in the power of managing human skills for solving real problems, by elevating our capabilities and our mindset. WeMe is a Norwegian Wellbeing Tech Startup developing AI-based SaaS tools for employees and managers that empowers businesses to integrate wellbeing through action based digital dialogue, preventing stress and burnout and improving overall performance. - Easy to implement and offering great value with immediate results improving mental and emotional health. Because Dialog Pays Off.

We are starting a new department for software development, and are at first looking for a head developer/coordinator. We will be developing software for existing customers that are in high demand of new solutions and integrations. We first wish to hire a senior full-stack developer with both front- and back-end skills. For the right employee, there will be an opportunity to become a partner. We are also searching for developers with primary competence in front- and backend development with JavaScript and/or PHP.

Radiocrafts is a leading RF module design and manufacturing company. Radiocrafts’ standard RF modules provide compact, easy-to-use, low cost, low power and high performance RF solutions for a large number of wireless applications using license-free ISM bands. By using modules OEM manufacturers without RF design knowledge can easily add wireless technology into their design, reducing time-to-market, cost of design, test, and compliance approvals. Radiocrafts also offers custom and application-specific product development, supporting customers from initial project ideas to volume product delivery. Radiocrafts currently provides solutions in the frequency bands 169, 433, 868, 915, and 2450 MHz, supporting radio protocols such as Wireless M-Bus, KNX, ZigBee, 6LoWPAN, SIGFOX, WIZE as well as proprietary solutions such as TinyMesh, RC232, and now our newest product lines, RIIoT and RIIM.

Din raskeste vei til fremtidsrettet forretningsdrift.Digital transformasjon er ikke et alternativ - det er en nødvendighet. Vi leder deg gjennom reise. Vårt ønske er at våre kunder skal jobbe proaktivt, fremfor reaktivt i deres forretningsutvikling. Med et sterkt partnerforhold til Microsoft har vi knyttet til oss bransjens mest komplette plattform for skybaserte forretningssystemer, og med vår lange erfaring på virksomhetsprosesser har vi utarbeidet løsninger på toppen av denne som gjør det mulig for bedrifter å drive en vei - fremover. Ingen hinder, kun kontinuerlig utvikling med kontroll- slik det bør være. Med Microsoft baserte skyløsninger er det enkelt for både store og små bedrifter å effektivisere arbeidsrutinene, styrke konkurranseevnen og samtidig ha mulighet for å drive aktiv forretningsutvikling uten å bli begrenset av smale forretningssystemer. Virksomheten kan starte med enkle løsninger og etter evne utvide bruksområde til å dekke de helt store og komplekse prosessene. Digital transformasjon er ikke et alternativ - det er en nødvendighet. Vi leder deg gjennom reisen

Zelo redefines how companies communicate internally. Streamline your internal communications by optimizing your reach. Compose, send, and track company updates across email, SMS, Teams & Slack in minutes. Use the Preferred Communication Channels Create great messages and distribute them across the channels your audience is most receptive to including email, SMS, Slack, MS Teams, and more.

NCON is a Norwegian-based business consultancy firm, built to help your business reach the next level. With years of broad experience in various industries and issues, we use our expertise to advance companies. Our specialty is to provide competitive services no matter the nature of your challenge and to be able to see the connection between significant factors. In order to best develop your business, we always aim to target and meet your specific needs. It is NCON’s focus to strive to offer our clients the best prices to performance ratio. NCON valuesThe deliverables of NCON are affected by strong principles, beliefs, and values, boiled down to three focus areas: Adaptable - Appreciating the exceptionality of every project, and being flexible when searching for the suited solutions. Open-minded - Looking beyond the known boundaries, striving to develop a new set of skills in order to stay present and relevant. Determination - With commitment and purpose-driven processes come results that are implementable and embedded in specific business strategies. NCON approach business consulting, product development, market research, innovative solutions... These are only some areas in which NCON can provide results for your business. The key lies within how NCON experts work, in an approach that turns a challenge into an opportunity. This approach is developed with the aim of being appropriate for all project processes, as the five steps below can be adjusted to a given situation. Defining client needs defining project goalsAgreements with clientAnalyse and develop the delivery of project

Amina Charging is a technology startup on a mission to give our planet a greener future by scaling the transition to electric vehicles (EV). We create environmental sustainability solutions grounded in sound business and global scalability. We work and play with curiosity, creativity and ambition. At Amina, we never compromise on sustainability, scale and sound business. We work with passion and insight, and prize impact and progress over process. We empower your creative autonomy but you will never struggle alone. We work as a team in an open culture that rewards sharing ideas and supporting each other.

Iterate is an ecosystem for digital innovation, and we like to describe ourselves as a company that builds companies. We contribute from A-Z when building, starting with creating concepts based on key insights to launching and improving products whilst living in the marketplace. We find the right team and work toward the company culture that enables us to deliver value to our customers quickly. The key to achieving this is reinvesting all our profits in the ideas of our employees, or selected entrepreneurs. Five years into this strategy, we own shares in fifteen ventures; all of which are showing promising results. Our 70 designers, developers, and product managers just moved into new locations in the center of Oslo. 
Close collaboration with our customers is key to our success. They provide domain know-how, and we provide tools, strategies, and experts. Together we uncover the best way that connects your strategy and idea with the market needs. Our goal is to achieve minimum risk and give our customers the best possible starting point for scaling, on their own, or in continued collaboration.

MyRent is a cloud-based system for managing tenants and rent payment. Our customers are businesses renting out apartments in Norway. MyRent has been running since 2012, and with help from a customized CRM system, we started getting customers early on. Today handle about 28 Million NOK in monthly payments for our customers. Our goal is to get this platform out in Scandinavia, after building the bases in Norway.

Oncoinvent AS is a privately held Norwegian company established in 2010. The company is committed to developing new innovative products to provide better treatment options to cancer patients. The innovations being developed by Oncoinvent AS are a result of the extensive experience with the development of radionuclide-based cancer treatments of two of the founders, Dr. Roy H. Larsen and Professor of clinical oncology Øyvind S. Bruland. Larsen and Bruland are the inventors of the first FDA and EMA-approved alpha-emitting pharmaceutical product Xofigo® (Bayer AG), as well as of the beta-emitting radio-immunotherapeutic product candidate Betalutin® (Nordic Nanovector ASA). Oncoinvent's lead product candidate, Radspherin®, is a novel alpha-emitting radioactive microsphere designed for the treatment of metastatic cancers in body cavities. Radspherin® has been shown to cause a significant reduction in tumor cell growth. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be the treatment of peritoneal carcinomatosis. Clinical development will be conducted in collaboration with European and American clinical research centers.

Biozep is discovering and developing first-in-class drug products for the treatment of severe eye diseases which can lead to vision loss and where it is a high unmet medical need. Biozep has discovered novel drug substances based on bioactive lipids which modulate central pathways involved in the pathogenesis of eye diseases. Targets and biomarkers are identified based on a system biology approach combined with in-depth knowledge about bioactive lipids, their endogenous synthesis and mechanisms of action. Biozep has made a prototype drug product based on our lead compound for topical administration and the product will be tested in animal models in 2018. Our goal is to start clinical studies in 2020. Biozep is a company depending on both internal and external resources. Biozep has established its own laboratory in Oslo in order to do synthesis, purification, quality control and chemical development in-house. The biological testing of the drug substances is performed in collaboration with carefully selected contract research organizations both in Europe and the USA. In order to reach the market as fast as possible and to reduce risk, Biozep will seek strategic partnerships early in the drug development phase. Biozep seeks partners with complementary competence and with resources to conduct clinical trials and with market access. We are already in dialogue with potential partners and hope to sign an agreement in 2018-19.

Yetz is a new distribution platform for product lines such as insurance, electricity, telecom, and finance. At launch, we will offer both insurance and power. We utilize strong incentives towards our customers and partners to share the concept, by giving them an affiliate commission. Monthly payment is based on the turnover of customers they have referred. Two fully owned sister companies Yetz Strøm og Yetz Forsikring.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

Zirius Kompetanse is a two-year-old company that delivers all training for the users of Zirius ERP.  We specialize in e-learning, but also hold courses at different locations in Norway on the system Zirius, accounting, VAT rules, and changes. As Zirius expands, so do we, so now we also will cover payroll-system, and HR and will make a training program for new hires, etc. We use Moodle as our LMS (Learning Management System), and use a local provider in Lillehammer, who is the only Norwegian Moodle partner.   We also make promo-videoes for Zirius, our customers, and other companies. Zirius Kompetanse started with Sissel Rogne as Manager, and a board consisting of the owners, which is Zirius and a few of the sales offices. I have hired one person for Project Management and video production. I have a vision of doing social entrepreneurship and have a good dialog with NAV. The person I hired came through a training program in NAV and ended up getting a work contract. We have built a good course portfolio, and are ready to start a more active sales process, which we need more marketing funds to do, and we need to upgrade our LMS, make integrations with other sites, and hire one more person to work with course development.

A bio-and medtech Company developing and selling proprietary solutions for using oxygen in various applications. Currently focussing on beverages (water, sports- and isotonic drinks), wound healing, cosmetics and fish farming. Licensing platform technology for applying oxygent to other products. Oxy Solutions is a privately held Norwegian based biotech company that has developed and patented an innovative technology for highly oxygenating liquid. Oxy Solutions'​ core business and strategy is to develop, document, IP protect, and commercialize the technology primarily within wound healing. The company has an in-house R&D facility in Norway. The company has funding from the Norwegian Research Council. Oxy Solutions is in possession of patented technology that makes it possible to greatly increase the dissolved level of oxygen in water. Tests have indicated stable levels in excess of 70 mg/l, or approximately 10 times higher than previously thought possible.